Arturo Molina, shared a post on LinkedIn:
“Standing ovation during the American Society of Clinical Oncology (ASCO) Plenary Session yesterday highlighting the outstanding results from the RASolute-302 randomized study of daraxonrasib vs chemotherapy for 2nd-line treatment of metastatic pancreatic cancer. This was an emotional moment for the world’s oncology community.
Daraxonrasib doubled median overall survival and significantly delayed deterioration of symptoms while offering a more favorable safety profile than chemotherapy.
Congrats Revolution Medicines! Daraxonrasib represents a long awaited victory for patients with pancreatic cancer, as clinical trials are testing this agent in earlier disease states.
Another important step in our battle against cancer!
Inspirational American Society of Clinical Oncology (ASCO) annual meeting with so many practice-changing presentations!”
Other articles on OncoDaily.